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Abstract: PURPOSE. To develop a HPLC method
for assay of dibudipine in biological fluids and to study
its pharmacokinetics in the rat. METHODS. HPLC: 2
µl (20 µg/ml) mebudipine as internal standard, 0.2
ml NaOH 1 M and 2 ml ethyl acetate were added to
0.2 ml of rat plasma. The mixture was shaken for 10
min, centrifuged, and the supernatant was dried under
nitrogen. The dissolved residue was injected to a C18
analytical column. Mobile phase flowed at 1 ml/min
with a composition of methanol--water-acetonitrile
(70-25-5). The eluent was monitored at 238 nm. Phar-
macokinetic study: plasma samples were collected peri-
odically after intravenous (0.5 mg/kg) or oral (10 mg/
kg) administration of dibudipine to rats (n = 4/group).
In addition, separate groups of animals were adminis-
tered 0.5 mg/kg doses of the drug for serial collection
of brain, heart, kidney and liver (n = 4/time). The
concentration of the drug in tissue or plasma was
assayed using the above HPLC method. RESULTS.
Calibration curves were linear over a concentration of
10-1000 ng/ml and CV was less than 10%. Dibudipine
showed a bi-exponential decline after IV injection in
the rats with a t1/2 beta of 2.5 ± 0.5(mean ± SE) hr.
Oral bioavailability was low. Distribution of dibu-
dipine to the examined tissues was rapid, and with the
exception of the brain, the concentrations of the drug
in all tissues were higher than the plasma levels CON-
CLUSIONS. The HPLC method was simple and con-
venient. Moreover, it could be applied to investigations
of the pharmacokinetics of dibudipine in the rat.
INTRODUCTION
Dibudipine, [bis-t-butyl, -1, 4-dihydro-2, 6-dimethyl-4 -
(3-nitrophenyl)-3, 5-pyridine dicarboxylate] is a new 1,
4-dihydropyridine (Figure 1) with calcium channel
blocker activity that was synthesized for the first time
in our laboratory [1]. In pervious studies, it was shown
that dibudipine had comparable pharmacological effect
with nifedipine while offering some advantages such as
longer biological half-life, longer time to reach peak
effect and more vasoselectivity [1, 2]. The HPLC
method of mebudipine assay was published previously
and dibudipine was used as an internal standard [3]. In
this study, high performance liquid chromatography
of dibudipine in plasma and tissues is described. Phar-
macokinetics of dibudipine after single intravenous
injection and oral administration are also studied.
Figure 1: Chemical structure of a) dibudipine and b)
mebudipine (internal standard).346
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Chemicals
Dibudipine and the internal standard (IS, mebudipine)
were synthesized in our laboratories [1]. HPLC grade
methanol, acetonitrile and ethyl acetate were pur-
chased from Merck (E. Merck, 64271 Darmstadt, Ger-
many). All other reagents were analytical grade or
higher. 
HPLC system
The HPLC system consisted of a Waters chromatogra-
phy system (Waters Chromatography Division, Mil-
ford, MA, USA) including a 600 controller, a 600
pump, a 486 UV tunable absorbance detector, a 7725i
Rheodyne manual injector and Yonglin Data module
attached to a PC. An analytical column (Novapack
ODS, 5 µm, 4.6 mm × 250 mm) was used for all anal-
ysis. The mobile phase consisted of methanol-water-
acetonitrile (70-25-5). The chromatography was per-
formed at ambient temperature at flow rate of 1 ml/
min and the eluent was monitored at 238 nm.
Standard Solutions
Stock solution of dibudipine and mebudipine were pre-
pared in methanol (1 mg/ml), protected from light and
stored at -20o until used. Solutions of 20 and 1 µg/ml
were prepared by diluting the stock solution in metha-
nol. The stability of these solutions was compared
against a freshly prepared stock solution. Standard
curves for plasma were prepared by adding known
amounts of dibudipine to pooled blank plasma to yield
10-1000 ng/ml concentrations of the drug. 
Sample preparation
To 0.2 ml plasma sample were added 2 µl of IS (mebu-
dipine, 20 µg/ml) and 0.2 ml of 1M NaOH. The solu-
tion was mixed for a few seconds. Two ml ethyl acetate
was added to the solution, which was subsequently
shaken on a horizontal shaker for 10 min followed by
centrifugation at 12000 RPM for 10 min. The organic
layer was transferred to a clean glass tube and evapo-
rated to dryness under slow stream of nitrogen at
40oC. The resultant residue was reconstituted in 100
µl of mobile phase and 50 µl of final solution was
injected into the HPLC. Peak-height ratios of dibu-
dipine: IS in samples were used to calculate dibudipine
plasma and tissue concentrations from standards.
Extraction efficacy
The extraction efficiency was calculated by adding
known amount of dibudipine (10, 50,100, 500 and 750
ng/ml) to 0.2 ml rat plasma (n =4). Dibudipine was
extracted as described above, and the peak heights of
dibudipine from spiked plasma samples were com-
pared with the peak heights obtained after direct injec-
tion of 50 µl of 10, 50,100, 500 and 750 ng/ml
methanolic solutions of dibudipine.
Accuracy and Precision
For the determination of intra- and inter-day accuracy
and precision of the assay, aliquots of 0.2 ml of rat
plasma were spiked with 2 µl of 20 µg/ml of internal
standard and various quantities of dibudipine to yield
10, 50, 100, 500 and 750 ng/ml. Accuracy was
expressed as the mean% [(mean measured concentra-
tion)/(expected concentration)]× 100 [4]. Precision
was calculated as inter- and intra-day coefficient of vari-
ation [%CV= (SD/mean) × 100] [4].
PHARMACOKINETICS OF DIBUDIPINE IN RATS
Animal study 
Male Sprague-Dawley rats (200±25 g) were used. They
were allowed free access to food and water during
housing, but were fasted overnight before the study.
The drug was dissolved in polyethylene glygol 400 for
oral and intravenous administration. The animals were
anesthetized by intraperitoneal injection of 25% ure-
thane in isotonic saline (0.5 ml/100g). The external
iliac vein was cannulated with catheter and 0.5 ml of
heparin (500 IU in saline) was injected before blood
collection. In intravenous dosing, 0.5 mg /kg (1 ml/kg)
dibudipine was injected into common jugular vein
directly via a syringe with 23G needle after a small inci-
sion in neck. In oral dosing, 10 mg/kg (5ml/kg) was
gavaged into stomach using feeding tube. Blood sam-
ples (0.4 ml each time) were periodically collected from
external iliac vein. For blood volume compensation,
0.5 ml of saline was injected by catheter. Before dibu-
dipine dosing, 0.2 ml heparin diluted in saline (500u/
ml) was injected into jugular vein. Plasma samples
were obtained by centrifugation of the blood at 5000
rpm and stored at -20o until analysis. For measuring tis-
sue distribution, 0.5 mg/kg of dibudipine was injected
into external iliac vein and animals were killed by sev-
ering abdominal aorta at 5, 10, 20 and 30 min after347
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ately removed and washed in saline. One gram of tis-
sues was homogenized in 2 ml saline and centrifuged at
12000 rpm for 30 min. One ml of homogenate super-
natant was stored at -20o until analysis. 
Pharmacokinetics analysis
Plasma concentrations of dibudipine against time after
intravenous administration were fitted to following
two-exponential equation using least squares method
applying Excel program [5]:
Where A and B are the zero time intercepts of the two
components of the two-exponential equation and α
and β are the hybrid rate constants of the distribution
and elimination phases, respectively [6].
The area under plasma concentration (AUC0-•) for
intravenous injection was calculated as below [6 and 7]:
For oral dosing, AUC0-• was calculated using trapezoi-
dal rule; the highest experimental concentration value
was assumed the peak concentration (Cmax). Time to
reach Cmax was denoted as tmax. 
The absolute oral bioavailability (F) was calculated as
((AUCpo ×doseiv/ AUCiv × dosepo))×100.
RESULTS AND DISCUSSION
It was found that liquid phase extraction method
yielded the best results in comparison with solid phase
extraction method. Ethyl acetate showed good extrac-
tion efficiency (>85%) and clean blank chromato-
grams.
Typical chromatograms of blank plasma, spiked
plasma and actual sample obtained from the pharmaco-
kinetic study are shown in Figure 2. Retention time of
dibudipine and internal standard were approximately
16 and 7 min, respectively. The total HPLC run time
for each sample was about 20 min. There were no
interfering peaks in the blank plasma samples. Stan-
dard curves prepared for dibudipine in rat plasma were
linear over 10 to 1000 ng/ml. The mean (n=6) calibra-
tion curve for dibudipine was y= 0.0027x - 0.0241,
r2=0.997 where, y and x are the peak height ratio and
concentration (ng/ml), respectively. Detection limit
for dibudipine quantitation was 10 ng/ml..
Figure 2: Chromatograms of dibudipine in rat plasma A.)
blank rat plasma, B.) sample spiked with 100 ng/ml
dibudipine and 100 ng /ml IS, and C.) sample obtained 5
min after IV dose of 0.5 mg/kg of dibudipine. Peaks:
1=mebudipine (IS), 2=dibudipine
The accuracy of assay was between 90 and 110%, and
CV did not exceed 10% (Table 1)
Table 1: Intra and Interday variation of dibudipine assay
in rat plasma (n=4).
The method mentioned above was applied to pharma-
cokinetic study of dibudipine in rats. The plasma con-
centration-time course and pharmacokinetic
parameters of dibudipine after a single iv dose of 0.5
mg/kg are presented in Fig. 3 and Table 2, respec-
tively.348
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following intravenous bolus administration of 0.5 mg/kg
dibudipine to rats (n = 4).
The mean plasma concentration was 238 ng/ml at two
min after IV administration of 0.5 mg/kg dibudipine.
This concentration was declined bi-exponentially to 49
ng after 4 h with a terminal half-life (t1/2β) of 2.5 h
(Figure 3, Table 2).
Figure 3: Mean dibudipine plasma concentration-time
profile in the rats following IV administration of 0.5 mg/
kg of dibudipine. Each point represents the mean +/- SE
for four rats.
This half life (2.5 hr) was longer than half lives of other
dihydropyridines such as nicardipine (0.1 hr), benid-
ipine (0.5 hr), nisoldipine (0.4 hr), nitrendipine (1.3 hr),
felodipine (1.5 hr) and nilvadipine (1.3 hr) [8], but was
comparable to that of amlodipine [9]. Clearance of 1.24
l/h/kg for dibudipine (Table 2) was lower than maxi-
mum blood flow of rat liver (3.3 to 4.8 l/hr/kg)[10].
Systemic clearance of most dihydropyridines is equal
or higher than liver blood flow [8, 11 and 12]. Benid-
ipine [13], nisoldipine [14], nitrendipine [15], felo-
dipine [9], nilvadipine [12] and lacidipine [11] have
higher systemic clearance than dibudipine after intra-
venous administration. Dibudipine plasma concentra-
tion declined bi-exponentially (Fig. 3). Plasma
concentration of most dihydropyridines has shown bi-
or tri-exponential decline [8, 11, 12 , 14 and 15]. There-
fore, it appears that the distribution of dibudipine is
qualitatively similar to other dihydropyridines. The
large Vss of dibudipine (3.98 l/kg, Table 2) indicates
substantial distribution of the drug to various tissues
consistent with its lipophilicity. Overall, the kinetic
data (Table 2) suggest that the relatively long t1/2 of
dibudipine is due to its lower systemic clearance cou-
pled with a relatively large Vss, relative to other dihy-
dropyridines. 
As shown in Figure 4 and Table 3, after oral adminis-
tration the plasma concentration-time profiles of
unchanged dibudipine showed substantial interindivd-
ual variability.
Figure 4: Plasma concentration-time curve of unchanged
drug in individual rats after oral administration of 10
mg/kg dibudipine as a solution in PEG 400.
Table 3: Pharmacokinetic parameters of dibudipine
following oral administration of 10 mg/kg dibudipine to
rats (n = 4).
Mean oral bioavailability of dibudipine was very low
(< 2%, Table 3) and similar to oral bioavailability of
nilvadipine (4.3%) [16], barnidipine (11-18%) [8],
nitrendipine (11%) [15], nisoldipine (3.4%) [14] and
benidipine (3.1%) [13] in rats. Despite complete
absorption from GI tract, extensive first pass effect is a
common property of dihydropyridines like nicar-
dipine, nisoldipine, felodipine, nilvadipine and lacid-349
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this rule, and with an assumption of complete oral
absorption, first pass effect of dibudipine is likely to be
extensive in rats.
Dibudipine distribution in several tissues after iv injec-
tion of the drug is shown in Figure 5.
Figure 5: Concentration of unchanged dibudipine in
plasma, brain, heart, liver and kidney of the rats at 2, 5,
10 and 30 min after intravenous administration of 0.5
mg/kg dibudipine. Each group represents mean +/- SE
for four rats.
Ratios of dibudipine levels in heart, liver and kidney to
plasma were constant in various times after the drug
administration (2, 5, 10, 30 min), suggesting that these
tissues are in the same compartment as plasma (cen-
tral). In contrast, changes in the brain levels of dibu-
dipine with time were not parallel to its plasma profile.
Therefore, it is possible that brain is part of a periph-
eral compartment in dibudipine disposition [17].
Nevertheless, the concentrations of dibudipine in rat
brain were much lower than those in other tissues.
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